scispace - formally typeset
S

Susanta Datta

Researcher at University of Ottawa

Publications -  5
Citations -  275

Susanta Datta is an academic researcher from University of Ottawa. The author has contributed to research in topics: Wireless network & Dominating set. The author has an hindex of 4, co-authored 4 publications receiving 267 citations. Previous affiliations of Susanta Datta include Ottawa University.

Papers
More filters
Journal ArticleDOI

Internal Node and Shortcut Based Routing with Guaranteed Delivery in Wireless Networks

TL;DR: In this article, the authors further improved the performance of i>GFG algorithm by reducing its average hop count, by adding a sooner-back procedure for earlier escape from i>FACE mode.
Journal ArticleDOI

Power and cost aware localized routing with guaranteed delivery in unit graph based ad hoc networks

TL;DR: This paper proposes localized routing algorithms, aimed at minimizing total power for routing a message or maximizing the total number of routing tasks that a network can perform before a partition.
Proceedings ArticleDOI

Internal node and shortcut based routing with guaranteed delivery in wireless networks

TL;DR: A localized routing algorithm is obtained that guarantees delivery and has very low excess in terms of hop count compared to the shortest path algorithm and can be reduced to about half that of existing GFG algorithm.
Proceedings ArticleDOI

Power and cost aware localized routing with guaranteed delivery in unit graph based ad hoc networks: Research Articles

TL;DR: This paper proposes localized routing algorithms, aimed at minimizing total power for routing a message or maximizing the total number of routing tasks that a network can perform before a partition.
Journal ArticleDOI

Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination

Ana Strezova, +175 more
TL;DR: An interim analysis of this follow-up study of the ZOE-50/70 trials demonstrated that efficacy against herpes zoster remained high and the safety profile remained clinically acceptable, suggesting that the clinical benefit of the RZV in ≥50-year-olds is sustained up to 10 years.